Status:
RECRUITING
Early Tranexamic Acid and Modulating the Inflammatory Response in Sepsis
Lead Sponsor:
Assiut University
Conditions:
Sepsis
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
In this study, our aim is to investigate the role tranexamic acid in modulating inflammation in patients with sepsis.
Detailed Description
A written informed consent will be taken from the patients or their relatives.Patients will be assigned randomly to two groups (40 subjects each) with qSOFA ≥2. In (Group T) administer 1 gram of tran...
Eligibility Criteria
Inclusion
- Adults (age 18-65 years) of American society of anesthesiologists (ASA) I-II who will be diagnosed with sepsis by qSOFA ≥2
- \& needed ICU admission.
Exclusion
- Chronic renal failure
- Liver cirrhosis
- Bleeding disorders or current anticoagulant therapy
- Pregnancy or breastfeeding
- Impaired color vision
- Severe vascular ischemia, history of venous thrombosis \& pulmonary embolism
- Long term treatment with acetylsalicylic acid or non-steroidal anti-inflammatory drugs not discontinued before ICU admission
- Allergy to tranexamic acid (TXA)
Key Trial Info
Start Date :
June 5 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 30 2027
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04910464
Start Date
June 5 2021
End Date
January 30 2027
Last Update
August 5 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assiut university hospital
Asyut, Egypt